1. Pink Sheet
  2. >>Market Access

EU Health Emergency Response Authority Calls On Off-Patent Sector

‘We Need To Build More In Europe,’ Says HERA Boss

 
• By Dean Rudge

The director-general of the European Commission’s recently-formed Health Emergency Response Authority addressed delegates at the off-patent association Medicines for Europe’s 2022 annual conference, noting that HERA was preparing a report for post-summer as it assessed its priorities.

Alex Ramsay/Alamy Stock Photo
HERA's mission is to prevent, detect and rapidly respond to health emergencies • Source: Shutterstock (Alex Ramsay / Alamy Stock Photo/Alamy Stock Photo)

For Pierre Delsaux, director-general of the EU's newly-launched Health Emergency Response Authority (HERA), working with industry is fundamental. Speaking at a recent industry conference, he stressed the importance of continuing dialog with “all kinds of industry representatives" and keeping an open mind.

The HERA was launched last autumn by the European Commission to support the development, manufacturing, and deployment of medical countermeasures to deal with future health threats, in the wake of...

More from Market Access

GLP-1 Pricing ‘Paradigm Shift’ Possible, But Would It Meet Trump’s MFN Goals?

 
• By Cathy Kelly

For the Trump Administration, the blockbuster GLP-1 drugs for obesity have become a poster child for the disparity between US and foreign prices.

Japan Price Cuts For Epkinly and Lunsumio Following CEA

 
• By Lisa Takagi

Japan is cutting more drug reimbursement prices following cost effectiveness analysis and is applying the methodology to a new group of products including Wegovy and Leqembi.

Rocky Rollout Spells Trouble for Medicare Prescription Payment Plan

 
• By Lauren Flynn Kelly

Enrollment in the new Medicare Prescription Payment Plan was lower than expected in the first year and well below CMS expectations, and invoicing data indicates members are slow to pay.

PBM Investigation, Enforcement Action ‘Critical Priorities’ At FTC, Chair Says

 
• By Cathy Kelly

The new FTC chair addressed concerns that staffing cuts will undermine the commission’s commitment to pharmacy benefit manager oversight.

More from Pink Sheet

How Pharma Companies Can Mitigate The Impact Of US Tariffs On The Supply Chain

 
• By Ewan Townsend

If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.

‘The Question Is, What’s Going To Happen Next?’ – The Future For Biosimilars In Europe

 
• By Dave Wallace

With European biosimilars developers buoyed by recent regulatory moves, Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil discuss the next steps forward for the industry.